2. Induced Disease Models Products Metabolic Enzyme/Protease
  3. Immunology and Inflammatory Disease Models Digestive System Disease Models Endogenous Metabolite
  4. Pancreatitis Models Pancreatic Disease Models
  5. Taurocholic acid sodium salt hydrate

Taurocholic acid sodium salt hydrate  (Synonyms: Sodium taurocholate hydrate; N-Choloyltaurine sodium salt hydrate)

Cat. No.: HY-B1131 Purity: 98.50%
SDS COA Handling Instructions

Molarity Calculator

Taurocholic acid sodium salt hydrate (Sodium taurocholate hydrate) is a bile acid involved in the emulsification of fats.

For research use only. We do not sell to patients.

Taurocholic acid sodium salt hydrate Chemical Structure

Taurocholic acid sodium salt hydrate Chemical Structure

CAS No. : 345909-26-4

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
500 mg USD 30 In-stock
1 g USD 50 In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 13 publication(s) in Google Scholar

Other Forms of Taurocholic acid sodium salt hydrate:

Taurocholic acid sodium salt hydrate Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Taurocholic acid sodium salt hydrate (Sodium taurocholate hydrate) is a bile acid involved in the emulsification of fats.

IC50 & Target

Human Endogenous Metabolite

 

Microbial Metabolite

 

In Vivo

Nitrofurazone (15 or 25 mg/kg, rat, feed; 15 or 31 mg/kg, mice, feed) is carcinogenic in female rats and female mice[4].
Nitrofurazone (11 and 111 mg/kg/ day, Oral gavage for mice; 0.78 and 7.8 mg/kg/ day, Oral gavage for guinea pigs) has no antibacterial activity in mice and guinea pigs[5].
Pharmacokinetic Characteristics of Nitrofurazone in Male Albino Rabbits:
1. Nitrofurazone administered intravenously has a higher clearance constant (0.04) and a shorter elimination half-life (17.32 minutes). Oral administration of Nitrofurazone shows a lower clearance constant (0.002) and a longer elimination half-life (276.09 minutes).
2. The AUC0→∞ for intravenous and oral administrations of Nitrofurazone are 844.79 and 566.44, respectively.
3. Nitrofurazone administered orally has a longer mean residence time (956.1 minutes), while the mean residence time for intravenous administration is 496.3 minutes.
Nitrofurazone can be used for animal modeling, including the development of mammary tumor models[4][5][6][7].

Induction of Acute Pancreatitis[2]

Background
Taurocholic acid (sodium salt hydrate) induced the formation of interstitial edema and caused acinar cell vacuolization in the pancreatic lobules. Taurocholic acid (sodium salt hydrate) also increased serum amylase and lipase activities. Interstitial edema becomes one of the most important criteria for assessing pancreatic damage in acute pancreatitis[1].
Specific Mmodeling Methods
Rats: Wistar • male? • weighing 220-240 g[1]
Administration: 1 mL/kg • retrograde infusion into the common pancreaticobiliary duct • at a speed of 0.25 mL/min[1]
Mice: Balb/c and Wistar • male? • weighing 25-30 g and 250-300 g[2]
Administration: 1 mL/kg • retrograde infusion • perfusion for 8 h[2]
Note
(1) Before administration, mice were kept at room temperature of 23±1℃ and 50-60 % relative humidity with free access to water and chow on a 12-h light/dark cycle. They were allowed to adapt to this environment for 5 days before the experiment, and received no nourishment and free access to water for 12 h preoperatively[1][2].
(2) Pancreatic acinar cells were isolated freshly from Balb/c or C57/BL6J mice using a collagenase IV. Cells were treated under room temperature, and used within 4 hours after isolation[2].
Modeling Indicators
Histological analysis: Taurocholic acid (sodium salt hydrate) administration caused the formation of interstitial edema in the pancreas and an increase of pancreas weight. Acinar cell vacuolization was evident in the pancreatic lobules, accompanied by some foci of pancreatic hemorrhage and marked peritoneal ascites. A pyknotic nucleus was in the center of necrotic acinar cell with a bright border. Taurocholic acid (sodium salt hydrate) administration induced marked oedema, inflammatory cell infiltration and acinar cell necrosis[1][2].
Biochemical Analysis: Taurocholic acid (sodium salt hydrate) administration increased serum amylase and lipase activities[1].
Correlated Product(s): /
Opposite Product(s): Neuronostatin; Flavonoids 1

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

555.70

Formula

C26H46NNaO8S
CAS No.
Appearance

Solid

Color

White to yellow

SMILES

C[C@H](CCC(NCCS(=O)(O[Na])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C.O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : 125 mg/mL (224.94 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : ≥ 100 mg/mL (179.95 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.7995 mL 8.9977 mL 17.9953 mL
5 mM 0.3599 mL 1.7995 mL 3.5991 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (4.50 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (4.50 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (179.95 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 98.50%

SDS (393 KB)

COA (251 KB) HNMR (147 KB) RP-HPLC (214 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 1.7995 mL 8.9977 mL 17.9953 mL 44.9883 mL
5 mM 0.3599 mL 1.7995 mL 3.5991 mL 8.9977 mL
10 mM 0.1800 mL 0.8998 mL 1.7995 mL 4.4988 mL
15 mM 0.1200 mL 0.5998 mL 1.1997 mL 2.9992 mL
20 mM 0.0900 mL 0.4499 mL 0.8998 mL 2.2494 mL
25 mM 0.0720 mL 0.3599 mL 0.7198 mL 1.7995 mL
30 mM 0.0600 mL 0.2999 mL 0.5998 mL 1.4996 mL
40 mM 0.0450 mL 0.2249 mL 0.4499 mL 1.1247 mL
50 mM 0.0360 mL 0.1800 mL 0.3599 mL 0.8998 mL
60 mM 0.0300 mL 0.1500 mL 0.2999 mL 0.7498 mL
80 mM 0.0225 mL 0.1125 mL 0.2249 mL 0.5624 mL
100 mM 0.0180 mL 0.0900 mL 0.1800 mL 0.4499 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Taurocholic acid sodium salt hydrate Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Taurocholic acid sodium salt345909-26-4Sodium taurocholateN-Choloyltaurine sodium saltEndogenous MetaboliteInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Taurocholic acid sodium salt hydrate
Cat. No.:
HY-B1131
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.